



PRESS RELEASE

Crucell to Present at UBS Global Life Sciences Conference, New York, September 28

Leiden, The Netherlands, September 21, 2004 – Crucell N.V. (Euronext, NASDAQ: CRXL) has announced its President and CEO, Ronald Brus, will present at the UBS Global Life Sciences Conference to be held next week (September 27-30) at the Grand Hyatt New York.

Dr. Brus will present on Tuesday, September 28 at 2:30 PM Eastern time. A live audio webcast will be available during the presentation at www.ibb.ubs.com (find the conferences box in the middle of the page and follow the link for Webcast under the Global Life Sciences Conference heading) and will also be archived for subsequent replay three hours after the presentation until October 30, 2004.

About Crucell

Crucell N.V. is a biotechnology company focused on developing vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria and West Nile virus. The company's development programs include collaborations with Aventis Pasteur for influenza vaccines, the U.S. National Institutes of Health for Ebola and malaria vaccines, and GlaxoSmithKline (GSK), Walter Reed Army Institute of Research and New York University for a malaria vaccine. Crucell's products are based on its innovative PER.C6[®] technology, which offers a safer, more efficient way to produce biopharmaceuticals. The company licenses its PER.C6[®] technology to the biopharmaceutical industry on a mostly non-exclusive basis. Licensees and CMO partners include DSM Biologics, GSK, Centocor/J&J and Merck & Co., Inc. Crucell is headquartered in Leiden, The Netherlands, and is listed on the Euronext and NASDAQ stock exchanges (ticker symbol CRXL). For more information, please visit www.crucell.com.

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on February 27, 2004, and the section entitled "Risk Factors". The company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP).

For further information please contact:

Crucell N.V.
Elizabeth Goodwin
Director Investor Relations
Tel. +31 (0)71 524 8718
e.goodwin@crucell.com

Redington, Inc.
Thomas Redington
Tel. +1 212-926-1733
treddington@redingtoninc.com